Novartis announced the launch of a mobile research study called Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS)-a mobile research study for people with multiple sclerosis (MS)-that collects data through the participants’ smartphone, eliminating the need for clinic visits. The study is designed to gather sensor-based data from physical tasks and symptoms.
The study aims to expand understanding of the daily challenges patients with MS can have and to uncover new potential capacities of treatment effectiveness through real-time data collection from participants in their everyday life. Researchers will use the participants’ data to understand what it is like to live with MS.
The elevateMS study was developed in partnership with Sage Bionetworks and uses a mobile application that was built on the Apple ResearchKit platform. The platform allows participants to contribute from home or on the go, and allow researchers to collect data in the participant’s everyday life. The mobile app was designed with input from patients, neurologists, and advocates. To download the app and enroll in the study, click here.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.